Nursing Times There was no significantly increased risk among people who received fluvastatin or lovastatin . The absolute risk for incident diabetes was about 31 and 3...
HealthCanal.com Atorvastatin accounted for more than half of all new statin prescriptions followed by rosuvastatin, simvastatin, pravastatin, lovastatin and fluvastatin. The study used pravastatin-treated patients as the comparison group as pravastatin has been shown ...
Economic Times He admits that last year's recall of atorvastatin from the US happened at an unfortunate time and that Ranbaxy will be a financially healthy company by ...
Medical Xpress Titled Clinical Equivalence of Proprietary and Generic Atorvastatin in Lipid Clinic Patients, the paper covers a study that looked at a large group of patients who took both Lipitor and generic atorvastatin over a prolonged period of time, ultimately ...
CTV News The three drugs were atorvastatin, rosuvastatin and simvastatin , which are sold as Lipitor, Crestor and Zocor respectively. The researchers said no increased risk was seen with fluvastatin (which is sold under the brand names Lescol, Canef and Vastin ...
HealthCanal.com Atorvastatin accounted for more than half of all new statin prescriptions followed by rosuvastatin, simvastatin, pravastatin, lovastatin and fluvastatin. The study used pravastatin-treated patients as the comparison group as pravastatin has been shown ...
Toronto NewsFIX They studied 3,086 patients who had had a heart attack – assigning them to either the cholesterol-lowering drug atorvastatin , or placebo, within four days of hospitalisation. Less than two per cent of the patients suffered a stroke during the four ... and more »
The Hindu Ultimately, fate intervened and, in November 2012, Ranbaxy had to issue a massive recall notice for atorvastatin after glass particles were discovered in samples. The FDA backed off from any suggestion that it may have bungled its approvals process for ... and more »
Medical News Today ... events was highest for atorvastatin (30 outcomes per 1000 person-years) and rosuvastatin (34 per 1000 person-years). Simvastatin made up for 26 outcomes per 1000 person-years with both fluvastatin and lovastatin at 21 outcomes per 100 person-years.
GhanaWeb Their report said: "We found that patients treated with atorvastatin , rosuvastatin, or simvastatin were at increased risk of new onset diabetes compared with ...
